Rezolute (RZLT) Research Hub

Rezolute (RZLT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.82 USD (-0.91%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -6.10, market cap 0.47B. This hub links to the full technical, earnings and options research available for RZLT.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close3.82 USD (-0.91%)
52-week range3.37 USD – 5.64 USD
Trend regimeRange
14-day RSI38.4 (Bearish)
Trailing P/E-6.10
Market cap0.47B
Dividend yield0.00%
Next earnings2026-09-16

Available research for RZLT

Earnings

RZLT earnings date and last-quarter result: next report 2026-09-16, last quarter miss, P/E -6.10. Updated 2026-07-23.

Options: Covered Call

Covered Call on RZLT: how it works, illustrative setup around the real 3.82 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on RZLT: how it works, illustrative setup around the real 3.82 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on RZLT: how it works, illustrative setup around the real 3.82 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

RZLT technical analysis: range, last 3.82 USD, RSI 38.4, 52w range 3.37 USD–5.64 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is RZLT in?

Rezolute (RZLT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is RZLT in an uptrend or downtrend?

As of 2026-10-26, RZLT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is RZLT's trailing P/E ratio?

RZLT's trailing P/E is -6.10, with a market cap of 0.47B. See the earnings research page for full valuation detail.

When does RZLT next report earnings?

RZLT is next scheduled to report earnings on 2026-09-16.